amifostine anhydrous has been researched along with Nausea in 15 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2)." | 9.09 | Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. ( Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B, 1999) |
| "Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2)." | 5.09 | Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. ( Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B, 1999) |
| "High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs." | 3.88 | Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. ( Bashir, Q; Caimi, P; Champlin, R; Cooper, B; Covut, F; Creger, R; de Lima, M; Delgado, R; Gupta, V; Lazarus, HM; Malek, E; Qazilbash, M; Rondon, G; Vatsayan, A, 2018) |
| " We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy." | 3.71 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malek, E | 1 |
| Gupta, V | 1 |
| Creger, R | 1 |
| Caimi, P | 1 |
| Vatsayan, A | 1 |
| Covut, F | 1 |
| Bashir, Q | 1 |
| Champlin, R | 1 |
| Delgado, R | 1 |
| Rondon, G | 1 |
| Cooper, B | 1 |
| de Lima, M | 1 |
| Lazarus, HM | 1 |
| Qazilbash, M | 1 |
| Soref, CM | 1 |
| Hacker, TA | 1 |
| Fahl, WE | 1 |
| Anné, PR | 2 |
| Machtay, M | 1 |
| Rosenthal, DI | 1 |
| Brizel, DM | 1 |
| Morrison, WH | 1 |
| Irwin, DH | 1 |
| Chougule, PB | 1 |
| Estopinal, NC | 1 |
| Berson, A | 1 |
| Curran, WJ | 2 |
| Kligerman, MM | 1 |
| Blumberg, AL | 1 |
| Glick, JH | 1 |
| Nelson, DF | 1 |
| Glover, D | 1 |
| Yuhas, JM | 1 |
| Amols, HI | 1 |
| Goodman, RL | 1 |
| Cairnie, AB | 1 |
| Ramnath, N | 1 |
| LoRusso, P | 1 |
| Simon, M | 1 |
| Martino, S | 1 |
| Viele, CS | 1 |
| Holmes, BC | 1 |
| Gelmon, K | 1 |
| Eisenhauer, E | 1 |
| Bryce, C | 1 |
| Tolcher, A | 1 |
| Mayer, L | 1 |
| Tomlinson, E | 1 |
| Zee, B | 1 |
| Blackstein, M | 1 |
| Tomiak, E | 1 |
| Yau, J | 1 |
| Batist, G | 1 |
| Fisher, B | 1 |
| Iglesias, J | 1 |
| Hofmann, WK | 1 |
| Seipelt, G | 1 |
| Ottmann, OG | 1 |
| Kalina, U | 1 |
| Koschmieder, S | 1 |
| Brücher, J | 1 |
| Frickhofen, N | 1 |
| Klausmann, M | 1 |
| Mitrou, PS | 1 |
| Hoelzer, D | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Yavuz, AA | 1 |
| Aydin, F | 1 |
| Yavuz, MN | 1 |
| Ilis, E | 1 |
| Ozdemir, F | 1 |
| Koukourakis, MI | 1 |
| Giatromanolaki, A | 1 |
| Kouroussis, C | 1 |
| Kakolyris, S | 1 |
| Sivridis, E | 1 |
| Frangiadaki, C | 1 |
| Retalis, G | 1 |
| Georgoulias, V | 1 |
| Delioukina, ML | 1 |
| Prager, D | 1 |
| Parson, M | 1 |
| Hecht, JR | 1 |
| Rosen, P | 1 |
| Rosen, LS | 1 |
| Bogo, V | 1 |
2 reviews available for amifostine anhydrous and Nausea
| Article | Year |
|---|---|
Amifostine: drug profile and nursing implications of the first pancytoprotectant.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Humans; Nausea; Neoplasms; Premedication | 1998 |
Radiation: behavioral implications in space.
Topics: Amifostine; Animals; Behavior; Conditioning, Psychological; Humans; Nausea; Psychomotor Performance; | 1988 |
6 trials available for amifostine anhydrous and Nausea
| Article | Year |
|---|---|
A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Inciden | 2007 |
Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 1997 |
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Mod | 1999 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Pro | 2001 |
A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
Topics: Acute Disease; Amifostine; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Nausea; Radiat | 2002 |
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Pro | 2002 |
7 other studies available for amifostine anhydrous and Nausea
| Article | Year |
|---|---|
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
Topics: Adult; Aged; Amifostine; Case-Control Studies; Combined Modality Therapy; Diarrhea; Disease-Free Sur | 2018 |
A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.
Topics: Administration, Oral; Amifostine; Animals; Diamines; Drug Evaluation, Preclinical; Female; Ferrets; | 2012 |
Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
Topics: Amifostine; Blood Pressure; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Eval | 1981 |
Adverse effects of radioprotector WR2721.
Topics: Amifostine; Animals; Conditioning, Psychological; Diet; Dose-Response Relationship, Drug; Male; Naus | 1983 |
Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels.
Topics: Aged; Amifostine; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Drug Administration | 2000 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas | 2002 |